What did @haleighweaver5 actually say?
The creator described a personal journey: about a month and a half on brand-name Mounjaro (tirzepatide), then a switch to compounded semaglutide after losing coupon coverage, with roughly a year on compounded semaglutide since. That is the full extent of the medical claim here. No dosing figures, no specific weight loss numbers, and no direct comparison of efficacy between the two drugs. The video is essentially a disclosure of how cost shaped her treatment path, which is an honest and fairly common story right now.
The caption promotes "affordable compounded Semaglutide/Tirzepatide for Weightloss," which implies equivalency and efficacy between compounded and brand products. The video itself is less aggressive, but the framing still positions compounded products as straightforward substitutes for brand-name medications, and that framing has real clinical implications worth examining.
Does the science back this up?
The underlying premise, that GLP-1 and dual GIP/GLP-1 agonists produce meaningful weight loss, is well-supported. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed tirzepatide producing up to 22.5% body weight reduction at 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4 mg producing roughly 15% weight loss. These are not the same drugs, and that gap is clinically significant.
What the science does not support is treating compounded versions as equivalent to these tested formulations. The FDA has stated explicitly that compounded drugs are not FDA-approved and have not undergone the same safety and efficacy review. There are no published randomized controlled trials on compounded semaglutide. Pharmacy compounders, even licensed 503B outsourcing facilities, operate under different manufacturing standards than the pharmaceutical companies behind Wegovy or Ozempic.
What did they get wrong (or right)?
Credit where it is due: the creator did not make false efficacy claims, did not prescribe doses, and did not claim compounded semaglutide is identical to Wegovy. She shared a personal experience of cost-driven switching, which reflects reality for a large number of patients. That transparency is worth acknowledging.
What is problematic is the caption framing. Calling compounded products an "affordable" alternative implicitly suggests they deliver the same outcome. That is not established by evidence. There is also a real risk in the switch itself. Tirzepatide and semaglutide have different mechanisms. Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates only GLP-1. A patient switching between them is not continuing the same therapy at a lower price. They are changing drugs entirely, and that requires clinical supervision. Switching without medical guidance can mean inconsistent dosing, loss of tolerability gains, and unclear efficacy outcomes.
What should you actually know?
If cost is forcing you off a brand-name GLP-1 or GIP/GLP-1 medication, that is a real and valid problem. But a few things deserve your attention before you act on content like this.
- Compounded semaglutide is not the same as Wegovy or Ozempic. The FDA does not recognize them as equivalent. Some compounded versions have included salt forms of semaglutide not used in approved products, which raises additional safety questions.
- Switching from tirzepatide to semaglutide is a drug change, not just a brand change. These molecules work differently, and outcomes in trials are not interchangeable.
- The FDA removed semaglutide from its drug shortage list in 2024, which means most 503A compounders are no longer legally permitted to compound it. The legal landscape for these products is shifting quickly.
- A licensed clinician should be involved in any switch between GLP-1 class medications, particularly if you are managing diabetes or have cardiovascular risk factors.